Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2002 6
2003 6
2004 4
2005 1
2006 3
2007 6
2008 1
2009 3
2010 7
2011 3
2012 4
2013 3
2014 1
2015 7
2016 18
2017 11
2018 11
2019 15
2020 9
2021 24
2022 14
2023 20
2024 18
2025 35
2026 16

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

211 results

Results by year

Filters applied: . Clear all
Page 1
Nighttime blood pressure-targeted antihypertensive treatment.
Maruhashi T, Kinoshita Y, Ozono R, Nakamaru M, Ninomiya M, Oiwa J, Kawagoe T, Yoshida O, Matsumoto T, Fukunaga Y, Sumii K, Ueda H, Shiode N, Takahari K, Hayashi Y, Ono Y, Nakano Y, Takahashi M, Kihara Y, Higashi Y; the Hiroshima NOCTURNE Research Group. Maruhashi T, et al. Among authors: yoshida o. J Hypertens. 2025 May 1;43(5):887-896. doi: 10.1097/HJH.0000000000003998. Epub 2025 Mar 5. J Hypertens. 2025. PMID: 40079840 Clinical Trial.
Immune therapies against chronic hepatitis B.
Akbar SMF, Yoshida O, Hiasa Y. Akbar SMF, et al. Among authors: yoshida o. J Gastroenterol. 2022 Aug;57(8):517-528. doi: 10.1007/s00535-022-01890-8. Epub 2022 Jun 16. J Gastroenterol. 2022. PMID: 35708793 Free PMC article. Review.
Alpha-Fetoprotein and Des-Gamma-Carboxy Prothrombin-Based Tumor Marker Score for First-Line Immunotherapy Selection in Hepatocellular Carcinoma.
Tanaka K, Tsuji K, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Ishikawa T, Tajiri K, Ochi H, Toyoda H, Koshiyama Y, Ogawa C, Nishikawa H, Nishimura T, Hatanaka T, Kakizaki S, Noritake H, Kawata K, Naganuma A, Kosaka H, Matsui K, Matono T, Kuroda H, Yata Y, Tanaka H, Aoki T, Tamai H, Tada F, Ohama H, Kanayama Y, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Yoshida O, Imai M, Nakamura S, Enomoto H, Kaibori M, Kudo M, Hiasa Y, Kumada T; Real-life Practice Experts for HCC (RELPEC) Study Group; HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Tanaka K, et al. Among authors: yoshida o. Liver Cancer. 2025 Jul 21. doi: 10.1159/000547519. Online ahead of print. Liver Cancer. 2025. PMID: 41063740 Free PMC article.
Neutrophil-Lymphocyte Ratio Predicts Overall Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab.
Matono T, Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Nishikawa H, Tanaka K, Tsuji K, Ishikawa T, Tajiri K, Koshiyama Y, Toyoda H, Ogawa C, Hatanaka T, Kakizaki S, Kawata K, Ohama H, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Nishimura T, Imai M, Kosaka H, Naganuma A, Aoki T, Kuroda H, Yata Y, Tamai H, Matsuura T, Komatsu S, Ueda Y, Nakamura Y, Yoshida O, Nakamura S, Enomoto H, Kaibori M, Fukumoto T, Hiasa Y, Kudo M; Real‐life Practice Experts for HCC (RELPEC) Study Group and the Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group. Matono T, et al. Among authors: yoshida o. Hepatol Res. 2025 Sep;55(9):1285-1295. doi: 10.1111/hepr.14224. Epub 2025 Jun 14. Hepatol Res. 2025. PMID: 40515751
Incarcerated Amyand's Hernia.
Okita A, Yoshida O, Murakami M. Okita A, et al. Among authors: yoshida o. Acta Med Okayama. 2020 Apr;74(2):171-174. doi: 10.18926/AMO/58277. Acta Med Okayama. 2020. PMID: 32341593 Free article.
Efficacy and Safety of Durvalumab Plus Tremelimumab in Hepatocellular Carcinoma Patients With Portal Vein Thrombosis and High Tumor Burden: A Multicenter Retrospective Analysis.
Hatanaka T, Yata Y, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Kakizaki S, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Toyoda H, Koshiyama Y, Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Matsui K, Naganuma A, Tanaka H, Ohama H, Kuroda H, Matono T, Aoki T, Ochi H, Imai M, Nakamura S, Komatsu S, Tamai H, Okamura J, Kanayama Y, Tanaka K, Tada F, Yoshida O, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Matsuura T, Noritake H, Enomoto H, Kaibori M, Fukumoto T, Hiasa Y, Kudo M, Kumada T; Real‐life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Hatanaka T, et al. Among authors: yoshida o. Hepatol Res. 2026 Jan;56(1):89-99. doi: 10.1111/hepr.70033. Epub 2025 Sep 6. Hepatol Res. 2026. PMID: 40913797
Vascular Invasion Within the Resectability Criteria Is a Prognostic Factor in Patients Treated With Atezolizumab and Bevacizumab.
Matono T, Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Nishikawa H, Tanaka K, Tsuji K, Ishikawa T, Tajiri K, Koshiyama Y, Toyoda H, Ogawa C, Hatanaka T, Kakizaki S, Kawata K, Ohama H, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Nishimura T, Imai M, Kosaka H, Naganuma A, Aoki T, Kuroda H, Yata Y, Tamai H, Matsuura T, Komatsu S, Ueda Y, Nakamura Y, Yoshida O, Matsui K, Nakamura S, Enomoto H, Kaibori M, Fukumoto T, Hiasa Y, Kudo M; Real‐life Practice Experts for HCC (RELPEC) Study Group and the Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group. Matono T, et al. Among authors: yoshida o. Liver Int. 2025 Aug;45(8):e70217. doi: 10.1111/liv.70217. Liver Int. 2025. PMID: 40622190
Impact of time-of-day atezolizumab plus bevacizumab combination therapy infusion for unresectable hepatocellular carcinoma: A retrospective multicenter study.
Naganuma A, Kakizaki S, Hatanaka T, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Toyoda H, Koshiyama Y, Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Matsui K, Yata Y, Tanaka H, Ohama H, Kuroda H, Matono T, Aoki T, Ochi H, Imai M, Nakamura S, Kanayama Y, Tanaka K, Tada F, Yoshida O, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Enomoto H, Kaibori M, Hiasa Y, Kudo M, Kumada T; Real‐life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Naganuma A, et al. Among authors: yoshida o. Hepatol Res. 2025 May;55(5):741-751. doi: 10.1111/hepr.14171. Epub 2025 Feb 9. Hepatol Res. 2025. PMID: 40317628
Potential role of Geriatric Nutritional Risk Index as a risk factor for immune-mediated adverse events during durvalumab plus tremelimumab therapy in unresectable hepatocellular carcinoma.
Ohama H, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Tanaka H, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Nishikawa H, Imai M, Aoki T, Ochi H, Tamai H, Komatsu S, Tada F, Nakamura S, Nakamura Y, Miyake T, Yoshida O, Nouso K, Morishita A, Itokawa N, Okubo T, Arai T, Tsutsui A, Nagano T, Tanaka K, Matsuura T, Koshiyama Y, Kanayama Y, Noritake H, Enomoto H, Matsui K, Kaibori M, Fukumoto T, Hiasa Y, Kudo M, Kumada T; RELPEC Group and HCC 48 Group. Ohama H, et al. Among authors: yoshida o. J Gastroenterol. 2025 Nov;60(11):1427-1436. doi: 10.1007/s00535-025-02290-4. Epub 2025 Aug 20. J Gastroenterol. 2025. PMID: 40833596
211 results